Literature DB >> 16914902

Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.

Tetsuo Yamazaki1, Umihiko Sawada, Yoshimasa Kura, Takeyoshi Ito, Jin Takeuchi, Yoshihiro Hatta, Shingo Aikawa, Kazuhiro Takei, Hikaru Ishizuka, Minoru Saiki, Kumi Uenogawa.   

Abstract

We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL). Three of the 4 patients with unspecified PTCL (PTCLu) achieved complete response (CR); 1 patient relapsed and 1 died of secondary leukemia after consolidation therapy. All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years. The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT). Thus, our regimen appears to be effective for high-risk AILT and SPTCL. However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914902     DOI: 10.1159/000093637

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

1.  Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.

Authors:  Daisuke Kurita; Katsuhiro Miura; Masaru Nakagawa; Shimon Ohtake; Masashi Sakagami; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yukio Hirabayashi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Yoshihiro Hatta; Yoshimasa Kura; Masahiko Sugitani; Masami Takei
Journal:  Int J Hematol       Date:  2015-03-17       Impact factor: 2.490

2.  Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study.

Authors:  Robert E Hutchison; Joseph H Laver; Myron Chang; Tariq Muzzafar; Sunil Desai; Sharon Murphy; Molly Schwenn; Jonathan Shuster; Michael P Link
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

3.  The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

Authors:  Jew Win Kuan; Kian Meng Chang; Ngee Siang Lau; Purushothaman Visalachy; Sen Mui Tan; Tee Chuan Ong; Anselm Ting Su
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

4.  Peripheral T-cell lymphoma: review and updates of current management strategies.

Authors:  Tiffany Tang; Kevin Tay; Richard Quek; Miriam Tao; Soo Yong Tan; Leonard Tan; Soon Thye Lim
Journal:  Adv Hematol       Date:  2010-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.